tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARGX Stock Latest News

argenx Wins FDA Priority Review for VYVGART in Seronegative gMG
Company Announcementsargenx Wins FDA Priority Review for VYVGART in Seronegative gMG
3d ago
6K
ARGX
Argenx: Strong Vyvgart Execution, Deep Pipeline, and Vision 2030 Drive Compelling Buy-Rated Upside
PremiumRatings
Argenx: Strong Vyvgart Execution, Deep Pipeline, and Vision 2030 Drive Compelling Buy-Rated Upside
3d ago
ARGX
Argenx announces FDA acceptance of Vyvgart sBLA for priority review
PremiumThe Fly
Argenx announces FDA acceptance of Vyvgart sBLA for priority review
3d ago
ARGX
Argenx: Sustained Growth and Strategic Pipeline Upside Underpin Buy Rating
PremiumRatings
Argenx: Sustained Growth and Strategic Pipeline Upside Underpin Buy Rating
3d ago
ARGX
Argenx: Sustained Vyvgart Momentum and Expanding FcRn Pipeline Underpin Buy Rating and Attractive Risk‑Reward
PremiumRatings
Argenx: Sustained Vyvgart Momentum and Expanding FcRn Pipeline Underpin Buy Rating and Attractive Risk‑Reward
3d ago
ARGX
argenx Posts 90% Sales Surge and Maps Pivotal 2026 Pipeline, Leadership Transition
PremiumCompany Announcementsargenx Posts 90% Sales Surge and Maps Pivotal 2026 Pipeline, Leadership Transition
3d ago
6K
ARGX
Argenx Advances Combo Strategy in Myasthenia Gravis With New ADAPT Forward Study
Premium
Company Announcements
Argenx Advances Combo Strategy in Myasthenia Gravis With New ADAPT Forward Study
3d ago
ARGX
ADAPT Forward: How Argenx’s New Myasthenia Gravis Study Could Shape Its Growth Story
Premium
Company Announcements
ADAPT Forward: How Argenx’s New Myasthenia Gravis Study Could Shape Its Growth Story
3d ago
ARGX
Argenx reports preliminary Q4 revenue $1.29B, consensus $1.1B
PremiumThe Fly
Argenx reports preliminary Q4 revenue $1.29B, consensus $1.1B
4d ago
ARGX
Argenx appoints Sandrine Piret-Gerard chief commercialization officer
PremiumThe Fly
Argenx appoints Sandrine Piret-Gerard chief commercialization officer
4d ago
ARGX
GILD
Argenx price target raised to $1,030 from $950 at Truist
PremiumThe Fly
Argenx price target raised to $1,030 from $950 at Truist
8d ago
ARGX
Argenx price target raised to $1,160 from $1,110 at Morgan Stanley
PremiumThe Fly
Argenx price target raised to $1,160 from $1,110 at Morgan Stanley
8d ago
ARGX
Argenx price target lowered to $1,091 from $1,124 at Citi
PremiumThe FlyArgenx price target lowered to $1,091 from $1,124 at Citi
8d ago
ARGX
Argenx price target raised to EUR 880 from EUR 850 at Barclays
Premium
The Fly
Argenx price target raised to EUR 880 from EUR 850 at Barclays
9d ago
ARGX
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
Premium
The Fly
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
10d ago
ARGX
IMVT
argenx: Leadership Continuity and Pipeline Milestones Underpin Sustained Buy Rating and $1,006 Price Target
PremiumRatings
argenx: Leadership Continuity and Pipeline Milestones Underpin Sustained Buy Rating and $1,006 Price Target
10d ago
ARGX
argenx: Leadership Transition, Pipeline Strength, and Commercial Expansion Support Buy Rating and $915 Target
PremiumRatings
argenx: Leadership Transition, Pipeline Strength, and Commercial Expansion Support Buy Rating and $915 Target
10d ago
ARGX
Argenx Unveils CEO Succession as Co‑Founder Moves to Chair Role
PremiumCompany Announcements
Argenx Unveils CEO Succession as Co‑Founder Moves to Chair Role
11d ago
6K
ARGX
Argenx CEO Tim Van Hauwermeiren to transition to chair, Karen Massey to succeed
PremiumThe Fly
Argenx CEO Tim Van Hauwermeiren to transition to chair, Karen Massey to succeed
11d ago
ARGX
Argenx price target raised to $1,006 from $942 at BofA
PremiumThe FlyArgenx price target raised to $1,006 from $942 at BofA
28d ago
ARGX
Argenx price target raised to $1,160 from $1,085 at Guggenheim
Premium
The Fly
Argenx price target raised to $1,160 from $1,085 at Guggenheim
28d ago
ARGX
Argenx downgraded to Neutral from Outperform at Baird
Premium
The Fly
Argenx downgraded to Neutral from Outperform at Baird
29d ago
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >